Should rheumatoid factor in rheumatoid arthritis be sent to Davy Jones’s Locker?

References

• Moore TL, Dorner RW. Rheumatoid factors. Clin Biochem 1993;26:75–84.
   PubMed Web of Science ®Google Scholar
• Egeland T, Munthe E. The role of the laboratory in rheumatology. Rheumatoid factors. Clin Rheum Dis 1983;9:135–60.
   PubMedGoogle Scholar
• Renaudineau Y, Jamin C, Saraux A, Youinou P. Rheumatoid factor on a daily basis. Autoimmunity 2005;38:11–16.
   PubMed Web of Science ®Google Scholar
• van der Linden MPM, Batstra MR, Bakker-Jonges LE, Detert J, Bastian H, Scherer HU, . Toward a data-driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis. Is it sensible to look at levels of rheumatoid factor? Arthritis Rheum 2011; 63:1190–9.
   PubMedGoogle Scholar
• Shmerling RH, Delbanco TL. The rheumatoid factor: an analysis of clinical utility. Am J Med 1991;91:528–34.
   PubMed Web of Science ®Google Scholar
• Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rødevand E, Nossent JC. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway. Scand J Rheumatol 2009;38:240–5.
   PubMed Web of Science ®Google Scholar
• Ball J, Lawrence JS. Epidemiology of the sheep cell agglutination test. Ann Rheum Dis 1961;20:235–43.
   PubMed Web of Science ®Google Scholar
• Cathcart ES, O’Sullivan JB. A longitudinal study of rheumatoid factors in a New England town. Ann N Y Acad Sci 1969;168:41–51.
   PubMed Web of Science ®Google Scholar
• Gran JT, Johannessen A, Husby G. A study of IgM rheumatoid factors in a middle-aged population of Northern Norway. Clin Rheumatol 1984;3:163–8.
   PubMed Web of Science ®Google Scholar
• Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, . Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797–808.
   PubMed Web of Science ®Google Scholar
• Besada E, Nikolaisen C, Nossent H. Diagnostic value of antibodies against mutated citrullinated vimentin for rheumatoid arthritis. Clin Exp Rheumatol 2011;29:85–8.
   PubMedGoogle Scholar
• Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004;50:3485–94.
   PubMed Web of Science ®Google Scholar
• Reparon-Schuijt CC, van Esch WJ, van Kooten C, Schellekens GA, de Jong BA, van Venrooij WJ, . Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 2001;44:41–7.
   PubMed Web of Science ®Google Scholar
• Shmerling RH. Testing for anti-cyclic citrullinated peptide antibodies. Is it time to set this genie free? Arch Intern Med 2009;169:9–14.
   PubMedGoogle Scholar
• Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094–108.
   PubMed Web of Science ®Google Scholar
• van der Linden MP, van der Woude D, Ioan-Fascinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, . Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009;60:2232–41.
   PubMed Web of Science ®Google Scholar
• Gossec L, Combescure C, Rincheval N, Saraux A, Combe B, Dougados M. Relative clinical influence of clinical, laboratory and radiological investigations in early arthritis on the diagnosis of rheumatoid arthritis. Data from the French Early Arthritis cohort ESPOIR. J Rheumatol 2010;37:2486–92.
   Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, . 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569–81.
   Web of Science ®Google Scholar
• Aggarwal R, Liao K, Nair R, Ringold S, Costenbader KH. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum 2009;61:1472–83.
   PubMed Web of Science ®Google Scholar
• Ates A, Karaaslan Y, Aksaray S. Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol 2007;26:499–504.
   PubMedGoogle Scholar
• Jansen AL, van der Horst-Bruinsma IE, van Schaardenburg D, van de Stadt RJ, de Koning MH, Dijkmans BA. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002;29:2074–6.
   PubMed Web of Science ®Google Scholar
• Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, . Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005;32:231–8.
   PubMed Web of Science ®Google Scholar
• Schellekens GA, Visser H, de Jong BAW, van den Hoogen FHJ, Hazes JMW, Breedveld FC, . The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155–63.
   PubMed Web of Science ®Google Scholar
• Luime JJ, Colin EM, Hazes JM, Lubberts E. Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 2010; 69:337–44.
   PubMed Web of Science ®Google Scholar
• Bang H, Egerer K, Gauliard A, Luthke K, Rudolph PE, Fredenhagen G, . Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007;56:2503–11.
   PubMed Web of Science ®Google Scholar